secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0001664710-25-000005
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros halts entire Phase 2 PAH trial (all doses, placebo) on pericardial effusion safety
--------------------------------------------------------------------------------

- Voluntary halt of all dosing in TROPOS trial, including 1.5 mg/kg and placebo arms, due to new pericardial effusion adverse events.
- Previously halted 3.0 mg/kg and 4.5 mg/kg arms on Dec 12, 2024; now entire study terminated early.
- Patients to be monitored through end-of-trial visits; investigators and FDA notified.
- Company still expects to present topline data from all treatment arms in Q2 2025.
- CEO Jasbir Seehra cited patient safety as top priority; working with FDA and other regulators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000005/0001664710-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000005/kros-20250115.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer